GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Price-to-Operating-Cash-Flow

AnaptysBio (AnaptysBio) Price-to-Operating-Cash-Flow : (As of May. 31, 2024)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Price-to-Operating-Cash-Flow?

As of today (2024-05-31), AnaptysBio's share price is $23.94. AnaptysBio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.01. Hence, AnaptysBio's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for AnaptysBio's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 11 years, AnaptysBio's highest Price-to-Operating-Cash-Flow Ratio was 108.06. The lowest was 44.43. And the median was 75.26.

ANAB's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 25.32
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

AnaptysBio's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-1.39. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.01.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -105.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -16.50% per year.

During the past 11 years, AnaptysBio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 19.20% per year. The lowest was -105.20% per year. And the median was -44.80% per year.


AnaptysBio Price-to-Operating-Cash-Flow Historical Data

The historical data trend for AnaptysBio's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Price-to-Operating-Cash-Flow Chart

AnaptysBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AnaptysBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AnaptysBio's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, AnaptysBio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Price-to-Operating-Cash-Flow falls into.



AnaptysBio Price-to-Operating-Cash-Flow Calculation

AnaptysBio's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=23.94/-5.01
=

AnaptysBio's Share Price of today is $23.94.
AnaptysBio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

AnaptysBio Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio (AnaptysBio) Business Description

Industry
Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.
Executives
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Dennis Mulroy officer: Chief Financial Officer
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
James N Topper director 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301

AnaptysBio (AnaptysBio) Headlines

From GuruFocus

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

By GuruFocusNews GuruFocusNews 07-02-2022

AnaptysBio Announces Participation in Upcoming Investor Conferences

By sperokesalga sperokesalga 05-30-2023